Search

Your search keyword '"Dagostin, Marilia Ambiel"' showing total 11 results
Start Over Author "Dagostin, Marilia Ambiel" Language english
11 results on '"Dagostin, Marilia Ambiel"'

1. Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry

Author

Triggianese, Paola, Vitale, Antonio, Lopalco, Giuseppe, Mayrink Giardini, Henrique Ayres, Ciccia, Francesco, Al-Maghlouth, Ibrahim, Ruscitti, Piero, Sfikakis, Petros Paul, Iannone, Florenzo, de Brito Antonelli, Isabele Parente, Patrone, Martina, Asfina, Kazi Nur, Di Cola, Ilenia, Laskari, Katerina, Gaggiano, Carla, Tufan, Abdurrahman, Sfriso, Paolo, Dagna, Lorenzo, Giacomelli, Roberto, Hinojosa-Azaola, Andrea, Ragab, Gaafar, Fotis, Lampros, Direskeneli, Haner, Spedicato, Veronica, Dagostin, Marilia Ambiel, Iacono, Daniela, Ali, Hebatallah Hamed, Cipriani, Paola, Sota, Jurgen, Kardas, Riza Can, Bindoli, Sara, Campochiaro, Corrado, Navarini, Luca, Gentileschi, Stefano, Martín-Nares, Eduardo, Torres-Ruiz, Jiram, Saad, Moustafa Ali, Kourtesi, Katerina, Alibaz-Oner, Fatma, Sevik, Gizem, Iagnocco, Annamaria, Makowska, Joanna, Govoni, Marcello, Monti, Sara, Maggio, Maria Cristina, La Torre, Francesco, Del Giudice, Emanuela, Hernández-Rodríguez, José, Bartoloni, Elena, Emmi, Giacomo, Chimenti, Maria Sole, Maier, Armin, Simonini, Gabriele, Conti, Giovanni, Olivieri, Alma Nunzia, Tarsia, Maria, De Paulis, Amato, Lo Gullo, Alberto, Więsik-Szewczyk, Ewa, Viapiana, Ombretta, Ogunjimi, Benson, Tharwat, Samar, Erten, Sukran, Nuzzolese, Rossana, Karamanakos, Anastasios, Frassi, Micol, Conforti, Alessandro, Caggiano, Valeria, Marino, Achille, Sebastiani, Gian Domenico, Gidaro, Antonio, Tombetti, Enrico, Carubbi, Francesco, Rubegni, Giovanni, Cartocci, Alessandra, Balistreri, Alberto, Fabiani, Claudia, Frediani, Bruno, and Cantarini, Luca

Published
2023
Full Text
View/download PDF

2. Correction: Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry

Author

Triggianese, Paola, Vitale, Antonio, Lopalco, Giuseppe, Mayrink Giardini, Henrique Ayres, Ciccia, Francesco, Al-Maghlouth, Ibrahim, Ruscitti, Piero, Sfikakis, Petros Paul, Iannone, Florenzo, de Brito Antonelli, Isabele Parente, Patrone, Martina, Asfina, Kazi Nur, Di Cola, Ilenia, Laskari, Katerina, Gaggiano, Carla, Tufan, Abdurrahman, Sfriso, Paolo, Dagna, Lorenzo, Giacomelli, Roberto, Hinojosa-Azaola, Andrea, Ragab, Gaafar, Fotis, Lampros, Direskeneli, Haner, Spedicato, Veronica, Dagostin, Marilia Ambiel, Iacono, Daniela, Ali, Hebatallah Hamed, Cipriani, Paola, Sota, Jurgen, Kardas, Riza Can, Bindoli, Sara, Campochiaro, Corrado, Navarini, Luca, Gentileschi, Stefano, Martín-Nares, Eduardo, Torres-Ruiz, Jiram, Saad, Moustafa Ali, Kourtesi, Katerina, Alibaz-Oner, Fatma, Sevik, Gizem, Iagnocco, Annamaria, Makowska, Joanna, Govoni, Marcello, Monti, Sara, Maggio, Maria Cristina, La Torre, Francesco, Del Giudice, Emanuela, Hernández-Rodríguez, José, Bartoloni, Elena, Emmi, Giacomo, Chimenti, Maria Sole, Maier, Armin, Simonini, Gabriele, Conti, Giovanni, Olivieri, Alma Nunzia, Tarsia, Maria, De Paulis, Amato, Lo Gullo, Alberto, Więsik-Szewczyk, Ewa, Viapiana, Ombretta, Ogunjimi, Benson, Tharwat, Samar, Erten, Sukran, Nuzzolese, Rossana, Karamanakos, Anastasios, Frassi, Micol, Conforti, Alessandro, Caggiano, Valeria, Marino, Achille, Sebastiani, Gian Domenico, Gidaro, Antonio, Tombetti, Enrico, Carubbi, Francesco, Rubegni, Giovanni, Cartocci, Alessandra, Balistreri, Alberto, Fabiani, Claudia, Frediani, Bruno, and Cantarini, Luca

Published
2024
Full Text
View/download PDF

3. Development and implementation of the AIDA International Registry for patients with Behçet’s disease

Author

Vitale, Antonio, Della Casa, Francesca, Ragab, Gaafar, Almaghlouth, Ibrahim A., Lopalco, Giuseppe, Pereira, Rosa Maria, Guerriero, Silvana, Govoni, Marcello, Sfikakis, Petros P., Giacomelli, Roberto, Ciccia, Francesco, Monti, Sara, Ruscitti, Piero, Piga, Matteo, Lomater, Claudia, Tufan, Abdurrahman, Opris-Belinski, Daniela, Emmi, Giacomo, Hernández-Rodríguez, José, Şahin, Ali, Sebastiani, Gian Domenico, Bartoloni, Elena, Akkoç, Nurullah, Gündüz, Özgül Soysal, Cattalini, Marco, Conti, Giovanni, Hatemi, Gulen, Maier, Armin, Parronchi, Paola, Del Giudice, Emanuela, Erten, Sukran, Insalaco, Antonella, Li Gobbi, Francesca, Maggio, Maria Cristina, Shahram, Farhad, Caggiano, Valeria, Hegazy, Mohamed Tharwat, Asfina, Kazi Nur, Morrone, Maria, Prado, Leandro L., Dammacco, Rosanna, Ruffilli, Francesca, Arida, Aikaterini, Navarini, Luca, Pantano, Ilenia, Cavagna, Lorenzo, Conforti, Alessandro, Cauli, Alberto, Marucco, Elena Maria, Kucuk, Hamit, Ionescu, Ruxandra, Mattioli, Irene, Espinosa, Gerard, Araújo, Olga, Karkaş, Burak, Canofari, Claudia, Sota, Jurgen, Laymouna, Ahmed Hatem, Bedaiwi, Asma. A., Colella, Sergio, Giardini, Henrique Ayres M., Albano, Valeria, Lo Monaco, Andrea, Fragoulis, George E., Kardas, Riza Can, Berlengiero, Virginia, Hussein, Mohamed A., Ricci, Francesca, La Torre, Francesco, Rigante, Donato, Więsik-Szewczyk, Ewa, Frassi, Micol, Gentileschi, Stefano, Tosi, Gian Marco, Dagostin, Marilia Ambiel, Mahmoud, Ayman Abdel-Monem Ahmed, Tarsia, Maria, Alessio, Giovanni, Cimaz, Rolando, Giani, Teresa, Gaggiano, Carla, Iannone, Florenzo, Cipriani, Paola, Mourabi, Mariam, Spedicato, Veronica, Barneschi, Sara, Aragona, Emma, Balistreri, Alberto, Frediani, Bruno, Fabiani, Claudia, and Cantarini, Luca

Published
2022
Full Text
View/download PDF

4. The Systemic Score May Identify Life‐Threatening Evolution in Still Disease: Data from the GIRRCS AOSD‐Study Group and the AIDA Network Still Disease Registry.

Author

Ruscitti, Piero, Masedu, Francesco, Vitale, Antonio, Caggiano, Valeria, Di Cola, Ilenia, Cipriani, Paola, Valenti, Marco, Mayrink Giardini, Henrique A, de Brito Antonelli, Isabele Parente, Dagostin, Marilia Ambiel, Lopalco, Giuseppe, Iannone, Florenzo, Maria, Morrone, Almaghlouth, Ibrahim A, Asfina, Kazi Nur, Ali, Hebatallah Hamed, Ciccia, Francesco, Iacono, Daniela, Pantano, Ilenia, and Mauro, Daniele

Subjects
RHEUMATOID arthritis diagnosis, RISK assessment, RHEUMATOID arthritis, SCIENTIFIC observation, SEVERITY of illness index, REPORTING of diseases, CHI-squared test, DESCRIPTIVE statistics, LONGITUDINAL method, ODDS ratio, LIVER diseases, RESEARCH, LUNG diseases, MACROPHAGE activation syndrome, CONFIDENCE intervals, DISEASE progression, DISEASE risk factors, DISEASE complications
Abstract

Objective: We aimed to evaluate the clinical usefulness of the systemic score in the prediction of life‐threatening evolution in Still disease. We also aimed to assess the clinical relevance of each component of the systemic score in predicting life‐threatening evolution and to derive patient subsets accordingly. Methods: A multicenter, observational, prospective study was designed including patients included in the Gruppo Italiano Di Ricerca in Reumatologia Clinica e Sperimentale Adult‐Onset Still Disease Study Group and the Autoinflammatory Disease Alliance Network Still Disease Registry. Patients were assessed to see if the variables to derive the systemic score were available. The life‐threatening evolution was defined as mortality, whatever the clinical course, and/or macrophage activation syndrome, a secondary hemophagocytic lymphohistiocytosis associated with a poor prognosis. Results: A total of 597 patients with Still disease were assessed (mean ± SD age 36.6 ± 17.3 years; male 44.4%). The systemic score, assessed as a continuous variable, significantly predicted the life‐threatening evolution (odds ratio [OR] 1.24; 95% confidence interval [CI] 1.07–1.42; P = 0.004). A systemic score ≥7 also significantly predicted the likelihood of a patient experiencing life‐threatening evolution (OR 3.36; 95% CI 1.81–6.25; P < 0.001). Assessing the clinical relevance of each component of the systemic score, liver involvement (OR 1.68; 95% CI 1.48–2.67; P = 0.031) and lung disease (OR 2.12; 95% CI 1.14–4.49; P = 0.042) both significantly predicted life‐threatening evolution. The clinical characteristics of patients with liver involvement and lung disease were derived, highlighting their relevance in multiorgan disease manifestations. Conclusion: The clinical utility of the systemic score was shown in identifying Still disease at a higher risk of life‐threatening evolution in a large cohort. Furthermore, the clinical relevance of liver involvement and lung disease was highlighted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Empyema caused by infection with Clostridium septicum in a patient with lung cancer

Author

Kreling, Gabriel Afonso Dutra, Dagostin, Marilia Ambiel, and Park, Marcelo

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, lcsh:RC705-779, medicine.medical_specialty, Fatal outcome, biology, business.industry, 030106 microbiology, MEDLINE, lcsh:Diseases of the respiratory system, medicine.disease, biology.organism_classification, Empyema, Clostridium septicum, 03 medical and health sciences, X ray computed, Carcinoma, medicine, Radiology, business, Lung cancer, Letter to the Editor

7. Development and implementation of the AIDA International Registry for patients with Behçet's disease

Author

Vitale, A, Della Casa, F, Ragab, G, Almaghlouth, Ia, Lopalco, G, Pereira, Rm, Guerriero, S, Govoni, M, Sfikakis, Pp, Giacomelli, R, Ciccia, F, Monti, S, Ruscitti, P, Piga, M, Lomater, C, Tufan, A, Opris-Belinski, D, Emmi, G, Hernández-Rodríguez, J, Şahin, A, Sebastiani, Gd, Bartoloni, E, Akkoç, N, Gündüz, Ös, Cattalini, M, Conti, Giorgio, Hatemi, G, Maier, A, Parronchi, P, Del Giudice, E, Erten, S, Insalaco, A, Li Gobbi, F, Maggio, Mc, Shahram, F, Caggiano, V, Hegazy, Mt, Asfina, Kn, Morrone, M, Prado, Ll, Dammacco, R, Ruffilli, F, Arida, A, Navarini, L, Pantano, I, Cavagna, L, Conforti, A, Cauli, A, Marucco, Em, Kucuk, H, Ionescu, R, Mattioli, I, Espinosa, G, Araújo, O, Karkaş, B, Canofari, C, Sota, J, Laymouna, Ah, Bedaiwi, Aa, Colella, S, Giardini, Ham, Albano, V, Lo Monaco, A, Fragoulis, Ge, Kardas, Rc, Berlengiero, V, Hussein, Ma, Ricci, F, La Torre, F, Rigante, Donato, Więsik-Szewczyk, E, Frassi, M, Gentileschi, S, Tosi, Gm, Dagostin, Ma, Mahmoud, Aaa, Tarsia, M, Alessio, G, Cimaz, R, Giani, T, Gaggiano, C, Iannone, F, Cipriani, P, Mourabi, M, Spedicato, V, Barneschi, S, Aragona, E, Balistreri, A, Frediani, B, Fabiani, C, Cantarini, L, Autoinflammatory Diseases Alliance (AIDA) Network, Vitale, Antonio, Della Casa, Francesca, Ragab, Gaafar, Almaghlouth, Ibrahim A, Lopalco, Giuseppe, Pereira, Rosa Maria, Guerriero, Silvana, Govoni, Marcello, Sfikakis, Petros P, Giacomelli, Roberto, Ciccia, Francesco, Monti, Sara, Ruscitti, Piero, Piga, Matteo, Lomater, Claudia, Tufan, Abdurrahman, Opris-Belinski, Daniela, Emmi, Giacomo, Hernández-Rodríguez, José, Şahin, Ali, Sebastiani, Gian Domenico, Bartoloni, Elena, Akkoç, Nurullah, Gündüz, Özgül Soysal, Cattalini, Marco, Conti, Giovanni, Hatemi, Gulen, Maier, Armin, Parronchi, Paola, Del Giudice, Emanuela, Erten, Sukran, Insalaco, Antonella, Li Gobbi, Francesca, Maggio, Maria Cristina, Shahram, Farhad, Caggiano, Valeria, Hegazy, Mohamed Tharwat, Asfina, Kazi Nur, Morrone, Maria, Prado, Leandro L, Dammacco, Rosanna, Ruffilli, Francesca, Arida, Aikaterini, Navarini, Luca, Pantano, Ilenia, Cavagna, Lorenzo, Conforti, Alessandro, Cauli, Alberto, Marucco, Elena Maria, Kucuk, Hamit, Ionescu, Ruxandra, Mattioli, Irene, Espinosa, Gerard, Araújo, Olga, Karkaş, Burak, Canofari, Claudia, Sota, Jurgen, Laymouna, Ahmed Hatem, Bedaiwi, Asma A, Colella, Sergio, Giardini, Henrique Ayres M, Albano, Valeria, Lo Monaco, Andrea, Fragoulis, George E, Kardas, Riza Can, Berlengiero, Virginia, Hussein, Mohamed A, Ricci, Francesca, La Torre, Francesco, Rigante, Donato, Więsik-Szewczyk, Ewa, Frassi, Micol, Gentileschi, Stefano, Tosi, Gian Marco, Dagostin, Marilia Ambiel, Mahmoud, Ayman Abdel-Monem Ahmed, Tarsia, Maria, Alessio, Giovanni, Cimaz, Rolando, Giani, Teresa, Gaggiano, Carla, Iannone, Florenzo, Cipriani, Paola, Mourabi, Mariam, Spedicato, Veronica, Barneschi, Sara, Aragona, Emma, Balistreri, Alberto, Frediani, Bruno, Fabiani, Claudia, and Cantarini, Luca

Subjects
Adult, Registrie, Autoinflammatory disease, Registry, Settore MED/16 - REUMATOLOGIA, precision medicine, behçet’s disease, Settore MED/38 - Pediatria Generale E Specialistica, Retrospective Studie, Internal Medicine, Humans, Prospective Studies, Registries, Child, international registry, Retrospective Studies, Behçet's disease, autoinflammatory diseases, rare diseases, uveitis, Behcet Syndrome, Prospective Studie, Uveiti, Emergency Medicine, Rare disease, Human
Abstract

Purpose of the present paper is to point out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients with Behçet’s disease (BD). The Registry is a clinical physician-driven non-population- and electronic-based instrument implemented for the retrospective and prospective collection of real-life data about demographics, clinical, therapeutic, laboratory, instrumental and socioeconomic information from BD patients; the Registry is based on the Research Electronic Data Capture (REDCap) tool, which is thought to collect standardised information for clinical real-life research, and has been realised to change over time according to future scientific acquisitions and potentially communicate with other existing and future Registries dedicated to BD. Starting from January 31st, 2021, to February 7th, 2022, 110 centres from 23 countries in 4 continents have been involved. Fifty-four of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 175 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 5993 fields organised into 16 instruments, including patient’s demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. The development of the AIDA International Registry for BD patients will facilitate the collection of standardised data leading to real-world evidence, enabling international multicentre collaborative research through data sharing, international consultation, dissemination of knowledge, inclusion of patients and families, and ultimately optimisation of scientific efforts and implementation of standardised care.Trial registration NCT05200715 in 21/01/2022.

Published
2022

8. Giant Cell Arteritis : Current Advances in Pathogenesis and Treatment

Author

Pereira, Rosa and Dagostin, Marilia Ambiel

Subjects
Science / Life Sciences / Biochemistry
Abstract

Giant cell arteritis (GCA) is the most common vasculitis in adults, with the incidence increasing with the advancing age. The aorta and its branches, especially the carotid extracranial branches, are the classic targets of inflammation in GCA. Visual loss, upper limb ischemia, and stroke are complications described. Suspicion of GCA is a medical emergency, and patients need to be quickly diagnosed/treated to prevent irreversible damage. Headache is the most common symptom, and a new-onset headache in older adults should always raise the suspicion of GCA. Patients may also present with scalp tenderness or tongue/jaw pain. GCA is often found to be the cause of an obscure-origin fever in older patients. A positive temporal artery biopsy is considered the gold standard for the diagnosis, but imaging techniques enable the assessment of cranial and extracranial arteries and the aorta. Ultrasound of temporal arteries is recommended and noncompressible “halo” sign is the typical finding. PET, MRI, or CT may be useful for the detection of the disease in the aorta and other vessels. The treatment must be started promptly with prednisone 1 mg/kg/day. When visual symptoms/unilateral visual loss is present, methylprednisolone pulse is recommended. Methotrexate, leflunomide and tocilizumab may be effective and well-tolerated glucocorticoid-sparing agents in GCA. Cardiovascular diseases are the leading causes of death in patients.

Published
2020

9. Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's Disease.

Author

Vitale A, Caggiano V, Sfikakis PP, Dagna L, Lopalco G, Ragab G, La Torre F, Almaghlouth IA, Maggio MC, Sota J, Tufan A, Hinojosa-Azaola A, Iannone F, Loconte R, Laskari K, Direskeneli H, Ruscitti P, Morrone M, Mayrink Giardini HA, Panagiotopoulos A, Di Cola I, Martín-Nares E, Monti S, De Stefano L, Kardas RC, Duran R, Campochiaro C, Tomelleri A, Alabdulkareem AM, Gaggiano C, Tarsia M, Bartoloni E, Romeo M, Hussein MA, Laymouna AH, Parente de Brito Antonelli I, Dagostin MA, Fotis L, Bindoli S, Navarini L, Alibaz-Oner F, Sevik G, Frassi M, Ciccia F, Iacono D, Crisafulli F, Portincasa P, Jaber N, Kawakami-Campos PA, Wiesik-Szewczyk E, Iagnocco A, Simonini G, Sfriso P, Balistreri A, Giacomelli R, Conti G, Frediani B, Fabiani C, and Cantarini L

Abstract

Introduction: The effectiveness of canakinumab may change according to the different times it is used after Still's disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment., Methods: Patients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still's disease. Seventy-seven (51 females and 26 males) patients with Still's disease were included in the present study. In total, 39 (50.6%) patients underwent CAN as a first-line biologic agent, and the remaining 38 (49.4%) patients were treated with CAN as a second-line biologic agent or subsequent biologic agent., Results: No statistically significant differences were found between patients treated with CAN as a first-line biologic agent and those previously treated with other biologic agents in terms of the frequency of complete response ( p  =0.62), partial response ( p  =0.61), treatment failure ( p  >0.99), and frequency of patients discontinuing CAN due to lack or loss of efficacy ( p  =0.2). Of all the patients, 18 (23.4%) patients experienced disease relapse during canakinumab treatment, 9 patients were treated with canakinumab as a first-line biologic agent, and nine patients were treated with a second-line or subsequent biologic agent. No differences were found in the frequency of glucocorticoid use ( p  =0.34), daily glucocorticoid dosage ( p  =0.47), or concomitant methotrexate dosage ( p  =0.43) at the last assessment during CAN treatment., Conclusion: Canakinumab has proved to be effective in patients with Still's disease, regardless of its line of biologic treatment., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Vitale, Caggiano, Sfikakis, Dagna, Lopalco, Ragab, La Torre, Almaghlouth, Maggio, Sota, Tufan, Hinojosa-Azaola, Iannone, Loconte, Laskari, Direskeneli, Ruscitti, Morrone, Mayrink Giardini, Panagiotopoulos, Di Cola, Martín-Nares, Monti, De Stefano, Kardas, Duran, Campochiaro, Tomelleri, Alabdulkareem, Gaggiano, Tarsia, Bartoloni, Romeo, Hussein, Laymouna, Parente de Brito Antonelli, Dagostin, Fotis, Bindoli, Navarini, Alibaz-Oner, Sevik, Frassi, Ciccia, Iacono, Crisafulli, Portincasa, Jaber, Kawakami-Campos, Wiesik-Szewczyk, Iagnocco, Simonini, Sfriso, Balistreri, Giacomelli, Conti, Frediani, Fabiani and Cantarini.)

Published
2023
Full Text
View/download PDF

10. Still's disease continuum from childhood to elderly: data from the international AIDA Network Still's disease registry.

Author

Vitale A, Caggiano V, Lopalco G, Mayrink Giardini HA, Ciccia F, Almaghlouth IA, Ruscitti P, Sfikakis PP, Tufan A, Dagna L, Giacomelli R, Hinojosa-Azaola A, Ragab G, Direskeneli H, Fotis L, Sota J, Iannone F, Morrone M, de Brito Antonelli IP, Dagostin MA, Iacono D, Patrone M, Asfina K, Alanazi F, Di Cola I, Gaggiano C, Tektonidou MG, Kardas RC, Kucuk H, Campochiaro C, Tomelleri A, Navarini L, Berardicurti O, Martín-Nares E, Torres-Ruiz J, Mahmoud AAA, Alibaz-Oner F, Kourtesi K, Tarsia M, Sfriso P, Makowska J, Govoni M, La Torre F, Maggio MC, Monti S, Del Giudice E, Emmi G, Bartoloni E, Hernández-Rodríguez J, Gómez-Caverzaschi V, Maier A, Simonini G, Iagnocco A, Conti G, Olivieri AN, De Paulis A, Lo Gullo A, Viapiana O, Wiesik-Szewczyk E, Erten S, Ogunjimi B, Carubbi F, Tharwat S, Laskari K, Costi S, Triggianese P, Karamanakos A, Conforti A, Frassi M, Sebastiani GD, Gidaro A, Mauro A, Balistreri A, Fabiani C, Frediani B, and Cantarini L

Subjects
Adult, Humans, Child, Aged, Arthralgia, Still's Disease, Adult-Onset diagnosis, Still's Disease, Adult-Onset epidemiology, Still's Disease, Adult-Onset drug therapy, Arthritis, Juvenile
Abstract

Objective: Still's disease is more frequently observed in the paediatric context, but a delayed onset is not exceptional both in the adulthood and in the elderly. However, whether paediatric-onset, adult-onset and elderly-onset Still's disease represent expressions of the same disease continuum or different clinical entities is still a matter of controversy. The aim of this study is to search for any differences in demographic, clinical features and response to treatment between pediatric-onset, adult-onset and elderly-onset Still's disease., Methods: Subjects included in this study were drawn from the International AutoInflammatory Disease Alliance Network registry for patients with Still's disease., Results: A total of 411 patients suffering from Still's disease were enrolled; the disease occurred in the childhood in 65 (15.8%) patients, in the adult 314 (76.4%) patients and in the elderly in 32 (7.8%) patients. No statistically significant differences at post-hoc analysis were observed in demographic features of the disease between pediatric-onset, adult-onset and elderly-onset Still's disease. The salmon-coloured skin rash (p=0.004), arthritis (p=0.009) and abdominal pain (p=0.007) resulted significantly more frequent among paediatric patients than in adult cases, while pleuritis (p=0.015) and arthralgia (p<0.0001) were significantly more frequent among elderly-onset patients compared with paediatric-onset subjects. Regarding laboratory data, thrombocytosis was significantly more frequent among paediatric patients onset compared with adult-onset subjects (p<0.0001), while thrombocytopenia was more frequent among elderly-onset patients although statistical significance was only bordered. No substantial differences were observed in the response to treatments., Conclusions: Despite some minor difference between groups, overall, demographic, clinical, laboratory and treatments aspects of Still's disease were similarly observed in patients at all ages. This supports that pediatric-onset, adult-onset and elderly-onset Still's disease is the same clinical condition arising in different ages., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

11. Empyema caused by infection with Clostridium septicum in a patient with lung cancer.

Author

Kreling GAD, Dagostin MA, and Park M

Subjects
Carcinoma, Non-Small-Cell Lung complications, Clostridium Infections complications, Empyema, Pleural diagnostic imaging, Fatal Outcome, Humans, Lung Neoplasms complications, Male, Middle Aged, Tomography, X-Ray Computed, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Clostridium Infections diagnostic imaging, Clostridium septicum, Empyema, Pleural microbiology, Lung Neoplasms diagnostic imaging
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results